GiannoudisP, TzioupisC, AlmalkiT, et al: Fracture healing in osteoporotic fractures: is it really different? a basic science perspective. Injury38 (suppl 1): S90, 2007.1738349010.1016/j.injury.2007.02.014)| false
ConfortiA, ChimauleraC, MorettiU, et al: Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases. Curr Drug Safety2: 47, 2007.10.2174/157488607779315516)| false
Guidance Document for the Preparation of Investigational Device Exemptions and Pre-market Approval Applications for Bone Growth Stimulator Devices,US Food and Drug Administration, Rockville, MD, 1988.
Guidance Document for the Preparation of Investigational Device Exemptions and Pre-market Approval Applications for Bone Growth Stimulator Devices,
US Food and Drug Administration, Rockville, MD, 1988.)| false
MirandaMA, MoonMS:“Treatment Strategy for Nonunions and Malunions,”inSurgical Treatment of Orthopaedic Trauma, edited byJPStannard, AHSchmidt, PJKregor, Theime Medical Publishers, New York, 2007.
MirandaMA, MoonMS:“Treatment Strategy for Nonunions and Malunions,”in
Surgical Treatment of Orthopaedic Trauma, edited byJPStannard, AHSchmidt, PJKregor, Theime Medical Publishers, New York, 2007.)| false
RobinsonCM, Court-BrownCM, McQueenMM, et al: Estimating the risk of nonunion following nonoperative treatment of a clavicular fracture. J Bone Joint Surg Am86: 1359, 2004.10.2106/00004623-200407000-0000215252081)| false
World Health Organization: The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products,World Health Organization, Geneva, Switzerland, 2002. Available at: http://apps.who.int/medicinedocs/en/d/Js4893e/6.html. Accessed May 14, 2012.)| false
ClassenDC, PestotnikSL, EvansRS, et al: Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA277: 301, 1997.10.1001/jama.1997.035402800390319002492)| false
IMS Institute for Healthcare Informatics: IMS Institute reports U.S. spending on medicines grew 2.3 percent in 2010, to $307.4 billion. Press release. Available at: http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid= 1648679328d6f210VgnVCM100000ed152ca2RCRD&vgnextchannel=41a67900b55a5110VgnVCM10000071812ca2RCRD&vgnextfmt=default. Published April 19, 2011. Accessed April 23, 2011.)| false
SosaM, SaaveddraP, Gómez de TejadaMJ, et al: Beta-blocker use is associated with fragility fractures in postmenopausal women with coronary heart disease. Aging Clin Exp Res23: 112, 2011.20463439)| false
RejnmarkL, VestergaardP, MosekildeL:Treatment with betablockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens24: 581, 2006.
RejnmarkL, VestergaardP, MosekildeL:Treatment with betablockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens24: 581, 2006.10.1097/01.hjh.0000203845.26690.cb)| false
JamalSA, BrownerWS, BauerDC, et al: Warfarin use and risk for osteoporosis in elderly women: Study of Osteoporotic Fractures Research Group. Ann Intern Med210: 829, 1998.10.7326/0003-4819-128-10-199805150-00006)| false
SimonRR, BeaudinSM, JohnstonM, et al: Long-term treatment with sodium warfarin results in decreased femoral bone strength and cancellous bone volume in rats. Thromb Res105: 353, 2002.10.1016/S0049-3848(02)00035-X12031831)| false
WiensM, EtminanM, GillSS, et al: Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med260: 350, 2006.1696167210.1111/j.1365-2796.2006.01695.x)| false
GiannoudisPV, MacDonaldDA, MatthewsSJ, et al: Nonunion of the femoral diaphysis: the influence of reaming and nonsteroidal anti-inflammatory drugs. J Bone Joint Surg Br82: 655, 2000.10.1302/0301-620X.82B5.082065510963160)| false
PountosI, GeorgouliT, CaloriGM, et al: Do nonsteroidal anti-inflammatory drugs affect bone healing? a critical analysis[published online January 4, 2012]. ScientificWorldJournal2012. doi:10.1100/2012/606404.22272177)| false
VestergaardP, RejnmarkL, MosekildeL:Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int79: 76, 2006.10.1007/s00223-006-0021-716927047)| false
Van WunnikBP, WeijersPH, van HeldenSH, et al: Osteoporosis is not a risk factor for the development of nonunion: a cohort nested case-control study. Injury42: 1491, 2011.10.1016/j.injury.2011.08.019)| false
Recognizing the existence of adverse drug effects of frequently prescribed drugs can empower a clinician with knowledge to avoid dangerous adverse effects that may result in hazardous, negative patient outcomes on either fracture healing or bone health. Pharmacovigilance reports have described the influence of medications, allowing for bone health to be quite unpredictable.
First, mechanisms found in the medical literature of potential drug adverse effects regarding fracture healing are presented. Second, the 100 most frequently prescribed medications in 2010 are reviewed regarding adverse effects on fracture healing. These reported adverse effects are evaluated for medical causation. Last, a data table describing the 100 reviewed medications and their reported effects on fracture healing is provided.
The actual number of different medications in the review was 72. Reported drug adverse effects on bone and fracture healing occurred with 59 of the 72 drugs (81.9%). These adverse effects are either described as a definitive statement or represented by postmarketing case reports. Thirteen of the 72 review drugs (18.1%) did not have any description of the possible effects on bone health. A total of 301 cases reports describing delayed union, malunion, and nonunion of fractures represent 31 of the 72 medications reviewed (43.1%).
This review offers the health-care provider information regarding potential adverse drug effects on bone health. Empowered with this information, clinicians may assist their patients in maximizing pharmacologic outcomes by avoiding these reported harmful adverse effects.